Carlos Juan

6.6k total citations · 1 hit paper
92 papers, 5.2k citations indexed

About

Carlos Juan is a scholar working on Molecular Medicine, Molecular Biology and Endocrinology. According to data from OpenAlex, Carlos Juan has authored 92 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Medicine, 45 papers in Molecular Biology and 32 papers in Endocrinology. Recurrent topics in Carlos Juan's work include Antibiotic Resistance in Bacteria (81 papers), Bacterial biofilms and quorum sensing (41 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Carlos Juan is often cited by papers focused on Antibiotic Resistance in Bacteria (81 papers), Bacterial biofilms and quorum sensing (41 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Carlos Juan collaborates with scholars based in Spain, Sweden and United States. Carlos Juan's co-authors include Antonio Oliver, Antonio Oliver, Bartolomé Moyá, Laura Zamorano, Xavier Mulet, José Luis Pérez, Gabriel Cabot, Carla López-Causapé, Jesús Blázquez and Sebastián Albertí and has published in prestigious journals such as PLoS ONE, Scientific Reports and The FASEB Journal.

In The Last Decade

Carlos Juan

91 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The increasing threat of Pseudomonas aeruginosa high-risk clones

2015 478 citations Antonio Oliver, Xavier Mulet et al. Drug Resistance Updates profile →

Peers

Countries citing papers authored by Carlos Juan

Since Specialization

Citations

This map shows the geographic impact of Carlos Juan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Juan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Juan more than expected).

Fields of papers citing papers by Carlos Juan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Juan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Juan. The network helps show where Carlos Juan may publish in the future.

Co-authorship network of co-authors of Carlos Juan

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Juan. A scholar is included among the top collaborators of Carlos Juan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Juan. Carlos Juan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa 2024 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), (unknown), (unknown), Pablo A. Fraile-Ribot, (unknown), Cristina Lasarte-Monterrubio, (unknown), (unknown), Bartolomé Moyá, Carlos Juan, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Antonio Oliver, Germán Bou, Jorge Arca-Suárez	12
2	Filling knowledge gaps related to AmpC-dependent β-lactam resistance in Enterobacter cloacae 2024 ·Scientific Reports ·Isabel M. Barceló, (unknown), Elena Jordana‐Lluch, Gabriel Torrens, Antonio Oliver, Carlos Juan	7
3	Bacterial virulence regulation through soluble peptidoglycan fragments sensing and response: knowledge gaps and therapeutic potential 2023 ·FEMS Microbiology Reviews ·(unknown), Isabel M. Barceló, Elena Jordana‐Lluch, Gabriel Torrens, Antonio Oliver, Carlos Juan	9
4	Effects of Inhaled Corticosteroids on the Innate Immunological Response to Pseudomonas aeruginosa Infection in Patients with COPD 2022 ·International Journal of Molecular Sciences ·(unknown), Hanaa Shafiek, (unknown), (unknown), Elena Jordana‐Lluch, (unknown), Isabel M. Barceló, Carla López-Causapé, Antonio Oliver, Carlos Juan, Amanda Iglesias, Borja G. Cosío	7
5	6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics 2021 ·Journal of Medicinal Chemistry ·Juan Carlos Vázquez-Ucha, (unknown), Cristina Lasarte-Monterrubio, Emilio Lence, Jorge Arca-Suárez, Marı́a Maneiro, Eva Gato, Astrid Pérez, Marta Martínez-Guitián, Carlos Juan, Antonio Jesús Sánchez-Oliver, Germán Bou, Concepción González‐Bello, Alejandro Beceiro	15
6	Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones 2021 ·Journal of Antimicrobial Chemotherapy ·María A. Gomis-Font, Gabriel Cabot, (unknown), Laura Zamorano, Carlos Juan, Bartolomé Moyá, Antonio Oliver	21
7	Activity of mammalian peptidoglycan-targeting immunity against Pseudomonas aeruginosa 2020 ·Journal of Medical Microbiology ·Gabriel Torrens, (unknown), Antonio Oliver, Carlos Juan	6
8	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa 2020 ·Journal of Antimicrobial Chemotherapy ·María A. Gomis-Font, Gabriel Cabot, Irina Sánchez-Diener, Pablo A. Fraile-Ribot, Carlos Juan, Bartolomé Moyá, Laura Zamorano, Antonio Oliver	37
9	Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling 2019 ·mSystems ·Gabriel Torrens, Sara B. Hernández, Juan A. Ayala, Bartolomé Moyá, Carlos Juan, Felipe Cava, Antonio Oliver	59
10	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system 2017 ·PLoS ONE ·Gabriel Torrens, (unknown), Bartolomé Moyá, (unknown), Laura Zamorano, Gabriel Cabot, Jesús Blázquez, Juan A. Ayala, Antonio Oliver, Carlos Juan	30
11	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies 2016 ·International Journal of Antimicrobial Agents ·Sílvia Gómez-Zorrilla, Carlos Juan, Gabriel Cabot, Mariana Camoez, Fé Tubau, Antonio Oliver, M.Á. Domínguez, Javier Ariza, Carmen Peña	33
12	The increasing threat of Pseudomonas aeruginosa high-risk clones breakdown → 2015 ·Drug Resistance Updates ·Antonio Oliver, Xavier Mulet, Carla López-Causapé, Carlos Juan	478
13	First detection in Europe of the metallo-β-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa 2013 ·Clinical Microbiology and Infection ·Raúl Gilarranz Luengo, Carlos Juan, (unknown), Francisco Javier Chamizo-López, Fernando Artiles, (unknown), Antonio Oliver	27
14	VIM-2–producing Multidrug-ResistantPseudomonas aeruginosaST175 Clone, Spain 2012 ·Emerging infectious diseases ·Esther Viedma, Carlos Juan, Jennifer Villa, (unknown), María Ángeles Orellana, Francisca Sanz, Joaquín R. Otero, Antonio Oliver, Fernando Cháves	65
15	Challenges for accurate susceptibility testing, detection and interpretation of -lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study 2012 ·Journal of Antimicrobial Chemotherapy ·Carlos Juan, M. Carmen Conejo, Nuria Tormo, (unknown), Álvaro Pascual, Antonio Oliver	20
16	Unmanageable norovirus outbreak in a single resort located in the Dominican Republic 2010 ·Clinical Microbiology and Infection ·Antonio Doménech‐Sánchez, Carlos Juan, (unknown), (unknown)	13
17	β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein 2009 ·PLoS Pathogens ·Bartolomé Moyá, Andreas Dötsch, Carlos Juan, Jesús Blázquez, Laura Zamorano, Susanne Häußler, Antonio Oliver	235
18	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae 2008 ·Journal of Antimicrobial Chemotherapy ·(unknown), Carlos Juan, Tânia Curião, Bartolomé Moyá, Elisenda Miró, Jesús Oteo, Teresa M. Coque, Marı́a Pérez-Vázquez, José Campos, Rafael Cantón, Antonio Oliver, Ferrán Navarro, (unknown)	64
19	Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting 2005 ·Clinical Microbiology and Infection ·Carlos Juan, Olivia Gutiérrez, Antonio Oliver, Ignacio Ayestarán, Núria Borrell, José Luis Pérez	40
20	Caracterización molecular de un brote por Enterococcus faecalis resistente a los glucopéptidos en una unidad de cuidados intensivos 2005 ·Enfermedades Infecciosas y Microbiología Clínica ·María D. Macià, Carlos Juan, Antonio Oliver, (unknown), José L. Pérez	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact